Past potential treatments for recurrent heart attacks were based...

Past potential treatments for recurrent heart attacks were based on increasing HDL cholesterol concentration in the blood not it's function, the so called cholesterol efflux capacity. HDL being the good cholesterol works to remove LDL, the bad cholesterol, from the blood. CSL chose a different path forward than previous trials by creating a molecule (csl112) from human plasma that mimics HDL and actually increases the cholesterol efflux capacity, the function of HDL. This new molecule increases the cholesterol efflux capacity a mammoth fourfold at a time when cholesterol efflux is significantly inhibited during and after a heart attack due to inflammation. All this theory means nothing if csl112 doesn't work in practice. However, CSL have had three futility readouts during their phase 3 trial. All got the tick. The first two on safety which is critical to the FDA. And the third was based on efficacy. At the full year 2022 results Perrault was asked about the third futility readout by an analyst. His reply, not exactly quoting, was that it did not meet the high internal standard expectations of CSL but was still good by normal standards. Therefore, from the information shareholders have atm we know it works but how good. I guess it comes down to the efficacy. So if you were a betting man at this stage I think Bagus you would have to give W534220's bet more chance than yours. GLTA